...
首页> 外文期刊>BMC Complementary and Alternative Medicine >Ginsenoside Rb1 can ameliorate the key inflammatory cytokines TNF-α and IL-6 in a cancer cachexia mouse model
【24h】

Ginsenoside Rb1 can ameliorate the key inflammatory cytokines TNF-α and IL-6 in a cancer cachexia mouse model

机译:人参皂苷RB1可以改善癌症恶魔小鼠模型中的关键炎症细胞因子TNF-α和IL-6

获取原文
           

摘要

Cancer cachexia is a severe condition that leads to the death of advanced cancer patients, and approximately 50~80% of cancer patients have cancer cachexia. Ginseng extract has been reported to have substantial anticancer and immune-enhancing effects; however, no study has reported the use of ginseng alone to treat cancer cachexia. Our study’s purpose was to investigate the therapeutic effects of ginseng-related monomers or mixtures on a cancer cachexia mouse model. We selected BALB/c mice and injected the mice subcutaneously with C26 colon cancer cells to construct a cancer cachexia experimental animal model. The water extract of ginseng (WEG), two types of ginseng extracts (ginsenosides at doses of 5?mg/kg (GE5) and 50?mg/kg (GE50)) and ginsenoside Rb1 (Rb1) were used to treat cancer cachexia mice. Enzyme-linked immunosorbent assays (ELISAs) were used to analyze the inhibitory effects on two key inflammatory cytokines, tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6). Our experimental results show that GE5, GE50 and Rb1 significantly reduced the levels of TNF-α (P??0.01) and IL-6 (P??0.01), which are closely related to cancer cachexia; however, WEG, GE5, GE50 and Rb1 did not significantly improve the gastrocnemius muscle weight or the epididymal fat weight of mice with cancer cachexia. These results indicate that GE5, GE50 and Rb1 may be useful for reducing symptoms due to inflammation by reducing the TNF-α and IL-6 cytokine levels in cancer cachexia mice, thereby ameliorating the symptoms of cancer cachexia. Our results may be beneficial for future studies on the use of Chinese herbal medicines to treat cancer cachexia.
机译:癌症恶病症是一种严重的病情,导致晚期癌症患者的死亡,约50〜80%的癌症患者有癌症恶魔。据报道人参提取物具有大量的抗癌和免疫增强效果;然而,没有研究据报道,仅使用人参单独治疗癌症恶病症。我们的研究目的是探讨人参相关单体或混合物对癌症恶魔小鼠模型的治疗效果。我们选择了BALB / C小鼠并用C26结肠癌细胞皮下注射小鼠,以构建癌症恶魔症实验动物模型。人参(WEG)的水提取物,两种类型的人参提取物(剂量为5μlmO5×mg / kg(ge5)和50μlm5/ kg(ge50))和人参皂苷Rb1(Rb1)治疗癌症恶魔小鼠。酶联免疫吸附测定(ELISAS)用于分析对两个关键炎症细胞因子,肿瘤坏死因子-α(TNF-α)和白细胞介素-6(IL-6)的抑制作用。我们的实验结果表明,GE5,GE50和RB1显着降低了TNF-α的水平(P?<β01)和IL-6(P?<β01),其与癌症恶化密切相关;然而,WEG,GE5,GE50和RB1没有显着提高胃肠肌重或与癌症恶魔症的肠胃脂肪重量。这些结果表明GE5,GE50和RB1可用于通过降低癌症恶魔小鼠中的TNF-α和IL-6细胞因子水平而导致的症状减少,从而改善癌症恶化的症状。我们的成果可能有利于未来关于使用中草药治疗癌症恶病症的研究。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号